Nuvilex Study Could Eliminate Need for Daily Insulin Requirements for Diabetic Patients

Nuvilex Inc. (OTCQB:NVLX) announced that it is preparing for a large scale, late phase clinical trial to treat advanced pancreatic cancer and they are also using the same technology to study diabetes which, if successful, could possibly eliminate the need for daily insulin requirements.

As quoted in the press release:

Researchers are putting their focus squarely on those islet cells as they are the key to what can only be described as miracle science at Nuvilex. The company is doing some amazing things with its living cell encapsulation technology that could make life much simpler for those who suffer from diabetes.

Click here to read the full Nuvilex Inc. (OTCQB:NVLX) press release.